 |
 |
Innopran
WellCare of Ohio - Covered Families and Childrend; and Aged, Blind, or Disabled List of Medications Requiring Prior Authorization LABEL ILOZYME IMDUR IMMUNE GLOBULIN IMODIUM IMOGAM RABIES-HT IMOVAX RABIES I.D. IMOVAX RABIES VACCINE IMURAN IMURAN INAMRINONE INCRELEX INDERAL INDERAL INDERAL INDERAL LA INDERIDE LA INDERIDE-40 25 INDERIDE-40 25 INDERIDE-80 25 INDOCIN INDOCIN I.V. INDOCIN SR INDOLE-3-CARBINOL INFASURF INFERGEN INFLAMASE FORTE INFLAMASE MILD INFUMORPH INFUMORPH INNOHEP INNOPRAN XL INOCOR INPERSOL W 4.25% DEXTROSE INSPRA INTAL INTEGRILIN INTRALIPID INTRON A INTRON A PEN INTRON-A INVANZ INVEGA NO PA FOR ABD ; INVERSINE IOCARE BALANCED SALT IODIDES IODIDES IODINE IODINE IODINE STRONG IODOPEN GENERIC NAME AMYLASE LIPASE PROTEASE ISOSORBIDE MONONITRATE IMMU GLOBULIN, GAMMA IGG ; LOPERAMIDE HCL RABIES IMMUNE GLOBULIN RABIES VACCINE, HUMAN DIPLOI RABIES VACCINE, HUMAN DIPLOI AZATHIOPRINE AZATHIOPRINE SODIUM INAMRINONE LACTATE MECASERMIN PROPRANOLOL HCL PROPRANOLOL HYDROCHLORIDE PROPRANOLOL HYDROCHLORIDE PROPRANOLOL HCL HCTZ PROPRANOLOL HCL HCTZ PROPRANOLOL PROPRANOLOL HYDROCHLOROTHIA PROPRANOLOL HYDROCHLOROTHIA INDOMETHACIN INDOMETHACIN SODIUM TRIHYDR INDOMETHACIN INDOLE-3-CARBINOL CALFACTANT INTERFERON ALFACON-1 PREDNISOLONE SOD PHOSPHATE PREDNISOLONE SOD PHOSPHATE MORPHINE SULFATE MORPHINE SULFATE PF TINZAPARIN SODIUM, PORCINE PROPRANOLOL HCL AMRINONE LACTATE DIALYSIS SOLUTIONS EPLERENONE CROMOLYN SODIUM EPTIFIBATIDE FAT EMULSIONS INTERFERON ALFA-2B, RECOMB. INTERFERON ALFA-2B, RECOMB. INTERFERON ALFA-2B, RECOMB. ERTAPENEM SODIUM PALIPERIDONE MECAMYLAMINE HCL SODIUM CAL mg SLT REP ; POTA AMMONIUM IODIDE POTASSIUM I POTASSIUM IODIDE IODINE POTASSIUM IODIDE IODINE SODIUM IODIDE IODINE SODIUM IODIDE PA REASON LC LC MA-PC-NJ-14 LC MA-PC-NJ-14 MA-PC-NJ-14 MA-PC-NJ-14 LC LC MA-PC-NJ-14 MA-PC-NJ-14 LC LC LC LC MA-PC-NJ-14 LC MA-PC-NJ-14 MA-PC-NJ-14 MA-PC-NJ-14 LC LC MA-PC-NJ-1 MA-PC-NJ-1 MA-PC-NJ-14 LC MA-PC-NJ-14 MA-PC-NJ-14 LC LC LC MA-P-NJ-14 MA-PC-NJ-14 MA-PC-NJ-14 MA-PC-NJ-14 MA-PC-NJ-14 LC LC LC LC MA-PC-NJ-14 Page 37 of 81 ALTERNATIVE AMYLASE LIPASE PROTEASE ISOSORBIDE MONONITRATE REQUEST MUST MEET ESTABLISHED CRITERIA LOPERAMIDE HCL REQUEST MUST MEET ESTABLISHED CRITERIA REQUEST MUST MEET ESTABLISHED CRITERIA REQUEST MUST MEET ESTABLISHED CRITERIA AZATHIOPRINE AZATHIOPRINE REQUEST MUST MEET ESTABLISHED CRITERIA REQUEST MUST MEET ESTABLISHED CRITERIA PROPRANOLOL HCL PROPRANOLOL HCL PROPRANOLOL HCL PROPANOLOL SR HCTZ PROPRANOLOL HCTZ PROPRANOLOL HCTZ PROPRANOLOL PROPRANOLOL HYDROCHLOROTHIA INDOMETHACIN REQUEST MUST MEET ESTABLISHED CRITERIA INDOMETHACIN REQUEST MUST MEET ESTABLISHED CRITERIA REQUEST MUST MEET ESTABLISHED CRITERIA REQUEST MUST MEET ESTABLISHED CRITERIA PREDNISOLONE ACETATE PREDNISOLONE ACETATE REQUEST MUST MEET ESTABLISHED CRITERIA REQUEST MUST MEET ESTABLISHED CRITERIA REQUEST MUST MEET ESTABLISHED CRITERIA PROPRANOLOL HCL REQUEST MUST MEET ESTABLISHED CRITERIA REQUEST MUST MEET ESTABLISHED CRITERIA SPIRONOLACTONE CROMOLYN SODIUM Dipyridamole REQUEST MUST MEET ESTABLISHED CRITERIA REQUEST MUST MEET ESTABLISHED CRITERIA REQUEST MUST MEET ESTABLISHED CRITERIA REQUEST MUST MEET ESTABLISHED CRITERIA REQUEST MUST MEET ESTABLISHED CRITERIA RISPERDAL, SEROQUEL INVERSINE CROMOLYN SODIUM IODINE IODINE IODINE IODINE IODINE REQUEST MUST MEET ESTABLISHED CRITERIA Updated 6 10 08.
Although pregnancy can pose substantial risks for women with congenital heart disease, it remains feasible for most with suitable medical support. Pre-pregnancy counselling and multidisciplinary care including cardiologists, obstetricians, and anaesthetists are essential to help these women have their own children at the minimal possible risk and, thus, allow them to reach their full life potential.
METABOLIC MODIFIER ORFADIN ANTIHYPERTENSIVES CARDIAC DIGITEK TABS DIGOXIN LANOXICAPS LANOXIN ANTIANGINALS--Isosorbide Dinitrate ISOSORBIDE DINITRATE TABS ISOSORBIDE DINITRATE CR TBCR ISOSORBIDE DINITRATE ER TBCR ISOSORBIDE DINITRATE TD TBCR MONO-NITRATES ISOSORBIDE MONONITRATE TABS ISOSORBIDE MONONITRATE ER DILATRATE SR CPCR ISORDIL TABS ISORDIL TITRADOSE TABS ISOSORBIDE DINITRATE SUBL IMDUR TB24 ISMO TABS MONOKET TABS NITRO - OINTMENT CAP CR NITROBID OINT NITROGLYCERIN CPCR NITROL OINT NITRO-TIME CPCR NITRO - PATCHES 1 NITRO - SUBLINGUAL SPRAY NITROGLYCERIN PT24 NITREK PT24 NITRO-DUR PT 24 0.8mg MINITRAN PT24 NITROLINGUAL AERS NITROSTAT SUBL NITROTAB SUBL BETA BLOCKERS - NON SELECTIVE COREG TABS1 INDERAL LA CPCR LEVATOL TABS NADOLOL TABS PINDOLOL TABS PROPRANOLOL HCL SOLN PROPRANOLOL HCL TABS SOTALOL HCL TABS TIMOLOL MALEATE TABS BETA BLOCKERS - CARDIO SELECTIVE ACEBUTOLOL HCL CAPS ATENOLOL TABS BETAXOLOL HCL TABS BISOPROLOL FUMARATE TABS METOPROLOL TARTRATE TABS TOPROL XL TB241 KERLONE TABS LOPRESSOR TABS SECTRAL CAPS TENORMIN TABS ZEBETA TABS 1. Toprol XL is preferred over Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical Coreg for LVD. Toprol XL will exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug not need a PA for LVD or CAD interaction between another drug and the preferred drug s ; exists. if patient on anti-anginal, diuretic or ACE. BETAPACE TABS BETAPACE AF TABS CORGARD TABS INDERAL TABS INNOPRAN XL PROPRANOLOL HCL LA CPCR NITROLINGUAL SOLN NITROQUICK SUBL Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug s ; exists. NITRODISC PT24 NITRO-DUR PT24 Preferred products must be Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical used in specified order or PA exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug s ; exists. will be required. Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug s ; exists. Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug s ; exists. Approved for Type 1 hereditary tyrosinemia patients. Must include laboratory evidence of dx at first PA.
What effects do antimicrobials have on commensals in the human body? To answer this question, the effects they have on susceptible as opposed to resistant organisms must be examined. It is also necessary to understand the "bystander effects" of antimicrobials rather than their direct effects on pathogens. Broader knowledge of the effects of antimicrobials, particularly reduction of colonization resistance, may help prevent colonization with.
Dr Justine Agness-Soumahoro, Chef de Service du CSUS USAC HDY, BP V3, Abidjan, Cit de Trchville, Cte d' Ivoire. Dr Thomas Aisu, National Tuberculosis and Leprosy Programme, Ministry of Health, P.O. Box 16069, Wandegeya, Kampala, Uganda. Dr Pasakorn Akarasewi, Director, Tuberculosis 10 Chiangmai, 143 Sridonchai Road, Chiangmai, Thailand 50000. Dr Mary Grace Alwano-Edyegu, AIDS Information Centre, P.O. Box 10446, Kampala, Uganda. Dr Giorgio Antonucci, Centro Di Riferimento AIDS, Ospedale "Lazzaro Spallanzani", Via Portuense, 292-0149 Roma, Italy. Dr Amy Bloom, Global programme for Health, USAID, Ronald Reagan Building, 1300 Pennsylvania Avenue, Washington, D.C. 20523, USA. Dr Heiner Bucher, Medizinische Universitaets-Poliklinik, Kantonsspital Basel, CH-4031, Basel, Switzerland. Dr Hisbello Da Silva Campos, Centro de Referencia Prof. Helio Fraga, Est. De Curicica, 2.000, 22710-550 Rio de Janeiro, Brazil. Dr Richard E. Chaisson, Director, AIDS Service, Johns Hopkins University, 600 N. Wolfe Street, Carnegie 292, Baltimore, MD 21287-6220, USA. Dr Gavin Churchyard, P.O. Box 87, Welkom, Freestate 9460, South Africa. Dr David Cohn, Denver Disease Control Services, 605 Bannock Street, Denver, Colorado 80204, USA. Dr D. Coulibaly, Comit National de Lutte contre le SIDA les MST et la Tuberculose, Ministere de la Sante Publique, 04 B.P. 2113, Abidjan 04, Republique de Cte d' Ivoire. Dr Kevin De Cock; Centre for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA. Dr Susan Foster, Dept. of Public Health and Policy, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom. Dr Enrico Girardi, Centro Di Riferimento AIDS, Ospedale "Lazzaro Spallanzani", Via Portuense, 292-00149 Roma, Italy. Dr Fred Gordin, Infectious Diseases 151B ; , 50 Irving Street NW, Washington D.C. 20422, USA. Dr Mattana Hanvanich, Department of Medicine Infectious Unit ; , Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand. Fr Michael Kelly, Kara Counselling and Training Trust, P.O. Box 37559, Lusaka, Zambia. Dr Daniel Kibuga, Head, National Leprosy and Tuberculosis Programme, Ministry of Health, Afya House, Cathedral Road, LG 05, P.O. Box 20781, Nairobi, Kenya. Professor Bernard Larouz, Institut de Medicin et Epidemiologie Africain, Hospital Claude Bernard, Paris, France. Dr Refiloe Matji, Director, TB Programme, Private Bag X828, Pretoria 0001, Republic of South Africa. Dr Alberto Matteelli, Department of Infectious and Tropical Diseases, Faculty of Medicine, University of Brescia, 25125 Brescia, Italy. Dr Francis Mubiru, The AIDS Support Organization, Mulago, P.O. Box 10443, Kampala, Uganda.
Medicine 1965; 44: 419-43 U. Initial observations of the Kaposi's sarcoma. JAMA 1984 and atacand.
NPS PHARMACEUTICALS, INC. AND SUBSIDIARIES Consolidated Statements of Stockholders' Equity Deficit ; and Comprehensive Income Loss ; -- Continued ; Years ended December 31, 2006, 2005 and 2004 In thousands, except share data.
Figure 4. Renal outcomes doubling of serum creatinine or ESRD ; as a function of both achieved SBP and treatments in proteinuric patients with type 2 diabetes 14 ; . Ave, average and lopid!
Internship In the year 2000 match we matched our third group of interns. The internship was established in the 1998-1999 academic year to meet the needs of applicants to our program that wished to pursue the entire postgraduate education curriculum in one location. Each year we have enrolled eight interns, and the program continues under the capable leadership of the Assistant Program Director, John B. Eck, M.D. The internship is a rotating internship designed to meet the educational needs of future anesthesiologists. It is a unique program at Duke, and unlike many transitional internships, is limited to interns who plan anesthesia careers at Duke. The internship emphasizes general medicine, surgery and pedi.
Innopran side
Popular categories anti-acidity zyloprim , prevacid , nexium , prilosec , gasex , carafate , zantac , bentyl , cytotec , protonix , reglan , aciphex anti-allergic asthma singulair , zyrtec , proventil , pulmicort inhaler , benadryl , claritin , phenergan , quibron-t , prednisolone , prednisone , fml forte , entocort , ventolin , flonase , periactin , decadron , synaral , rhinocort , foradil , serevent , clarinex , medrol , astelin , allegra , aristocort , beconase aq , deltasone , flovent anti-depressant anti-anxiety lexapro , celexa , loxitane , zyprexa , ashwagandha , risperdal , zyban , wellbutrin sr , prozac , desyrel , effexor , emsam , geodon , paxil , cymbalta , seroquel , sarafem , sinequan , buspar , atarax , pamelor , stress gum , tofranil , trazodone , 5-htp , haldol , endep , elavil , remeron , keppra , luvox , anafranil , abilify , zoloft , compazine anti-diabetic glycemil , amaryl , karela , diabecon , starlix , prandin , glucotrol xl , avandia , avandamet , actos , actoplus met , glucophage , vein support , benfotiamine , torsemide anti-fungus mycelex-g , gyne-lotrimin , lotrisone , grifulvin v , mentax , diflucan , nizoral , femcare , lamisil anti-herpes zovirax , neurontin , valtrex , bactroban , famvir antibiotics cipro , zithromax , trimox , levaquin , prograf , sumycin , isoniazid , myambutol , zyvox , noroxin , omnicef , vantin , keftab , stromectol , floxin , flagyl er , erythromycin , doxycycline , tetracycline , septilin , bactrim , cleocin , ceftin , amoxil , augmentin , cephalexin , biaxin , lincocin , maxaquin bestsellers viagra , cialis , viagra professional , cialis professional , viagra super active , viagra soft tabs , cialis soft tabs , vpxl , soma , carisoprodol , levitra professional , levitra , female viagra , tramadol , propecia , ultram , penis growth pills , penis growth oil , penis extender standard , phentrimine blood pressure cholesterol lipostatin , shuddha guggulu , lasuna , imdur , ismo , tricor , hyzaar , zetia , cordarone , procardia , pravachol , plendil , plavix , accupril , zocor , micardis , mevacor , lozol , lotensin , lopid , atacand , innopran xl , hytrin , diovan , crestor , cozaar , coreg , zestril , cardura , cardizem , trandate , lasix , vasodilan , capoten , vasotec , lisinopril , vytorin , zebeta , mexitil , norvasc , norpace cr , rythmol sr , calan , prinivil , altace , aldactone , aceon , lipitor , monoket , tenormin , avapro , toprol xl , inderal , adalat , lopressor , isoptin , coumadin , abana , doxazosin , hydrochlorothiazide , furosemide , clonidine , lanoxin , zestoretic , digoxin , metformin , omega 3-1 , torsemide , benicar , cholestoplex , avalide body-building ephedraxin , bcaa mass , creatine pure , extreme detox , noxide , pyruvitol , vanadyl , gluta-pep , creatine-1200 , testo-rex , cree-1200 , chromonexin , tribulus , alpha lipoic acid , coq10 , glucosamine sulfate , dhea , ribocree , l-glutamine , herbal testosterone , l-carnitine , energy patch , zma-power , thyroid booster , chrysin-xy , methox-400 , anabol-amp , dhea patch , l-arginine patch , ribose-atp , colostrum-800 , testosterone booster patch , l-arginine , gaba hgh booster ; , bcaa , anaphen hardcore , cee extreme , amino mass , hmb mass , anabolic mass , anabolic fusion , glutapower dental whitening touch-up kit , deluxe handheld plasma whitening tool , 2 sets of moldable mouth trays , deluxe whitening system with plasma lamp , 2 complete professional whitening kits , professional plasma tooth whitening kit female enhancement women's intimacy enhancer , women's intimacy enhancer cream , breast enhancement , breast enhancement gel , breast augmentation , bust enhancer , female sexual tonic , men attracting pheromones , brafix , breast enhancement gum , breast sculptor , quickbust , evegen , female sexual oil , breast enlargement patch general health strattera , rogaine , hangover helper , revia , prednisone , dramamine , parlodel , hydrea , vitaliq , lamictal , decadron , depakote , imuran , brahmi , styplon , mentat , triphala , cytoxan , cystone , herbolax , vitamin a & d , aricept , trileptal , antabuse , motilium , tulasi , mental booster , purim , lariam , pletal , cyklokapron , ophthacare , levothroid , thyroid booster , purinethol , requip , sustiva , sinemet , hair loss cream , zerit , copegus , epivir-hbv , exelon , kytril , leukeran , viramune , mysoline , oxytrol , topamax , atrovent , combivent , synthroid , detrol , diamox , abana , chloromint , dulcolax , ditropan , extreme thyrocin , vermox , echinacea , ginseng , acai , alpha lipoic acid , french red wine , phosphatidylserine , vein support , periactin , high absorption magnesium , prednisolone , reminyl , lanoxin , pilocarpine , ginkgo biloba patch , digoxin , antivert , meclizine , imodium , methotrexate , keppra , dilantin , nitrofurantoin gums new and lotensin.
Estimation of energy and protein requirements Nutritional interventions can only be effective if energy requirements are both accurately estimated and then achieved. The standard approach is to estimate energy requirements from basal energy expenditure, using regression equations and activity and stress factors see e-table 3 * ; . Energy requirements range from 85150 kJ kg. Protein requirements are usually set at 78% of energy needs, although severely ill or injured patients may require 1520% of their energy as protein. This is approximately 1.52.0 g of protein kg of body weight.2 Further research is required to characterise specific amino acid and micronutrient requirements in surgical patients.3 Ongoing monitoring is needed to evaluate the accuracy of the patient's estimated requirements. This also ensures that the patient is receiving the prescribed level of nutrition support to meet these requirements. Nutrition interventions options and outcomes.
`. an excellent, up-to-date, concise, comprehensive and authoritative review . a very useful book for anyone planning to use the drug for patient treatment in the clinical setting.' - S. Mulligan, Concord Repatriation Hospital, Australia This detailed clinical reference contains five main chapters on B-cell chronic lymphocytic leukemia, the road to remission from single agent intervention to combination therapy and onward ; , monoclonal antibodies in cancer the development of Campath-1H ; , Campath1H in B-CLL remissions of refractory disease ; , and the role of Campath-1H prior to bone marrow transplant in refractory B-CLL plus a concluding chapter on future perspectives and lozol.
Innopran children
| Innopran no prescriptionEw things in medicine are more difficult than a patient death. Except, perhaps apologizing for that death.
A subtropical cherry species requiring no chill to set fruit. Fruits are red to deep red in color, and similar to common supermarket cherry varieties in flavor. Medium to large sized tree, hardy to 19F. .00 #181 Psidium cattleianum Strawberry Guava Related to the tropical guava, produces small dark red skinned fruits to 1.5". Flesh is translucent, juicy, and not mealy like the tropical guava, with a tasty acidic-strawberry flavor. Very easy to grow as a con and mevacor.
Innopran sale
Enter a number greater than 0. Example: When 2 milligrams of a medication is administered, enter data as follows: 2.
|
We use the term trait broadly to refer to such constructs as personality traits, attitudes, and values, intrapsychic structures that develop through the complex interplay of social experience and genetic constitution. These constructs influence the fundamental processes of perception, interpretation, and action. Several researchers have noted commonalties between attitudes and traits Azjen, 1987; Blass, 1984; Sherman & Fazio, 1983 ; . Traits and attitudes are similar in that both function to explain consistencies in behavior and guide relevant perceptions through the processes of attention and encoding Sherman & Fazio, 1983 ; . We define trait relevance as the degree to which a trait is consequential in influencing an individual's thought, affect, and behavior. The more relevant a trait is to an individual, the more the individual can be said to be "traited" Baumeister & Tice, 1988; Reise & Waller, 1993 ; on the underlying construct and therefore the more likely the trait will influence behavior and experience. The relevance of a trait to an individual is to some extent independent of the individual's score on the underlying trait dimension. For example, an individual might score very low or very high on the trait of aggressiveness, but the underlying dimension of aggressiveness may not be relevant to the individual in terms of determining his or her behavior or experience. Biesanz, West, and Graziano 1998 ; noted that an assumption of differential trait relevance implies that the researcher must first determine where the individual falls on the trait dimension trait score or standing ; , and then determine the extent to which the trait influences the individual's experience and behavior trait relevance ; . In understanding the distinction between trait relevance and trait score in the context of personality traits, values, and attitudes, it is helpful to consider dimensions relevant to all people, such as height and weight. All people "have" height and weight height and weight are by definition relevant to all people ; , so the task of measurement involves simply determining where people fall along these dimensions. However, as we noted earlier, numerous personality and social psychologists have argued that people differ in the extent to which personality traits, values, and attitudes are relevant to them. For these dimensions, the researcher must determine not only where an individual falls on and micardis.
8. The balance between oxidative stress and expression of atherogenic or atheroprotective genes a. May determine whether or not an individual develops atherosclerosis b. Is important only in some individuals c. Is not influenced by the presence of diabetes or other diseases d. None of the above 9. Among markers of inflammation that have been identified, a. C-reactive protein is an acute phase protein, but it has not been correlated with coronary disease b. The cytokines and adhesion molecules are the only species that are predictive of coronary risk c. C-reactive protein is an acute phase reactant that is a prognostic indicator in acute myocardial infarction and predicts prospective coronary risk d. Only the acute phase proteins have a role in atherogenesis 10. Primary proinflammatory cytokines like IL-1 and TNF- a. Exert their effects independently of other cytokines b. Are not recognized to be important in atherogenesis c. Are only relevant to atherogenesis if they are derived from vascular tissue sources d. May stimulate expression of IL-6 11. In a large, prospective, case-control study of 12 proposed markers of cardiovascular disease in women, a. High-sensitivity C-reactive protein was the strongest univariate predictor of the risk of cardiovascular events b. C-reactive protein was equivalent to IL-6, as a predictive factor for cardiovascular events c. Differences between these factors were negligible d. Only LDL-C had predictive value for cardiovascular events.
Drug Name GUANABENZ ACETATE HYZAAR LOTREL 5-40 mg, 10-40 mg CAP TEKTURNA TEKTURNA HCT ALTACE ATACAND ATACAND HCT AZOR BENICAR BENICAR HCT CATAPRES-TTS LOTREL 2.5-10 mg, 5-10 mg, 5-20 mg, 10-20 mg CAP BETA BLOCKERS Generics acebutolol hcl atenolol bisoprolol fumarate carvedilol labetalol hcl tab metoprolol succinate metoprolol tartrate tab nadolol pindolol propranolol hcl cr propranolol hcl tab sorine sotalol hcl sotalol hcl af ; timolol maleate tab Brands BYSTOLIC INNOPRAN XL TOPROL XL COREG INDERAL LA PROPRANOLOL HCL SOLN and zocor.
II. Drugs 1. Hazard of smoking.
VOL. 45, 2001 TABLE 1. Properties of bacterial strains and plasmids used in this studya and accupril.
No. 342 670 ; Authors : Suputtamongkol Y, Newton PN, Angus B, Teja-Isavadharm P, Keeratithakul D, Rasameesoraj M, Pukrittayakamee S, White NJ. Title : A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria. Source : British Journal of Clinical Pharmacology. 52 6 ; : 655-661, 2001 Dec ; . Keywords : Artemether, Artesunate, Bioassay, Bioavailability, Combination, Malaria, Pharmacokinetics, Plasmodium Falciparum, Thailand.
Hydroxyamphetamine hydrobromide tropicamide, ophthalmic hydroxychloroquine, oral hydroxyurea, oral hydroxyzine hydrochloride, oral hydroxyzine pamoate, oral hydroxyzine, oral Hylaform hylan B gel, injection hylan G-F 20, injection Hyoscine * hyoscyamine, oral * hyoscyamine phenobarbital, oral Hyosophen Hyosophen Elixir HyperHep B * Hyperosmotic laxatives, oral * HyperRHO * Hyperstat HyperTET * Hyphed * HypoTears HypoTears PF Hytinic * Hytone * Hytrin * Hytuss 2X Capsules Hytuss Tablets Hyzaar * I-Vite ibandronate, oral * Iberet Filmtab Iberet-Folic-500 ibritumomab tiuxetan, infusion Ibu 200 * Ibu-tab * ibuprofen, oral * ibuprofen hydrocodone bitartrate, oral * ibuprofen oxycodone, oral Ibuprohm * ibutilide fumarate, injection ICAPS Plus ICAPS Plus Tablets ICAPS Time Release ICAPS Time Release Tablets Idamycin idarubicin, injection IDR idursulfase, injection Ifex ifosfamide, injection IGIM * IGIV * IL-11 IL-2 Illustrations eyedrops, how to put in * injection, how to give intramuscular shot subcutaneous shot * subcutaneous with aspiration medicines list metered-dose inhaler with a valved holding chamber, how to use metered-dose inhaler, how to use * suppository, how to use * vaginal medicine, how to use * vaginal ring, how to insert * iloprost, inhalation Ilosone * imatinib mesylate, oral Imdur * imidazole carboxamide, injection imiglucerase, injection imipenem cilastatin, injection imipramine pamoate, oral * imipramine, oral * imiquimod, topical Imitrex Injection Imitrex Nasal Spray Imitrex Tablets * immune globulin, IM * immune globulin, IV * immune globulin, subcutaneous infusion Imodium Imodium A-D Imodium A-D Advanced Imogam Rabies Imovax Rabies Imuran Imuran Injection inamrinone, injection Inapsine Increlex indapamide, oral Inderal * Inderal Injection * Inderal LA * Inderide * indinavir sulfate, oral Indocin * Indocin SR * Indocin Suppositories * Indomethacin SR * indomethacin, oral * indomethacin, rectal * Infanrix * Infant's FeverAll * Infant's Motrin * Infants' Tylenol Drops * Infasurf Infergen Inflamase Forte * Inflamase Mild Ophthalmic * infliximab, injection influenza vaccine, inactivated split-virion, injection influenza vaccine, injection Influenza Virus Vaccine H5N1 influenza virus vaccine live, intranasal * influenza virus vaccine, injection * Infumorph * Innofem * Innohep InnoPran XL * Inspra insulin aspart, injection rapidacting ; * insulin aspart insulin aspart protamine, injection premixed ; * insulin detemir, injection * insulin glargine, injection long-acting ; * insulin glulisine, injection * insulin lispro protamine suspension insulin lispro, injection premixed ; * insulin lispro, injection rapidacting ; * insulin, inhaled insulin, injection intermediateacting human ; * insulin, injection intermediateacting purified pork ; * insulin, injection premixed human ; * insulin, injection short-acting human ; * insulin, injection short-acting purified pork ; * Intal Aerosol Intal Solution Intal Spincaps Integrilin interferon alfa-2a, injection interferon alfa-2b, injection interferon alfa-n3, injection interferon alfacon-1, injection interferon beta-1a, injection interferon beta-1b, injection interleukin 11 interleukin-2 intrauterine copper contraceptive, device Intron-A Invagesic * Invagesic Forte * Invanz Invega Inversine Invirase Iobid DM Tablets iodoquinol, oral iodoquinol hydrocortisone, topical Ionil * Ionil-T PLUS Iopidine * ipecac, oral IPOL ipratropium bromide, inhalation * ipratropium bromide, nasal * ipratropium bromide albuterol sulfate, inhalation * Iprivask Iquix * irbesartan, oral * irbesartan hydrochlorothiazide, oral * Ircon * Iressa irinotecan hydrochloride, injection iron sucrose, injection iron supplements, oral * iron-polysaccharide, oral * ISMO * isocarboxazid, oral * Isochron * isometheptene dichloralphenazone acetaminophen, oral isoniazid, oral isoniazid pyrazinamide rifampin, oral isoniazid rifampin, oral isoproterenol, injection Isoptin * Isoptin SR * Isopto Atropine Isopto Cetamide * Isopto Tears Isordil Sublingual * Isordil Tembids * isosorbide dinitrate, oral * isosorbide dinitrate, sublingual * isosorbide dinitrate hydralazine, oral isosorbide mononitrate, oral * Isotrate ER * isotretinoin, oral isradipine, oral * Istalol * Isuprel itraconazole, oral * Iveegam * Iveegam EN * ivermectin, oral IvyBlock Jantoven * Januvia jojoba natural remedy ; Junel 1.5 30 21 * Junel 1 20 * Junel FE 1.5 30 * Junel FE 1 20 * Junior Strength Advil * Junior Strength Motrin * Junior Strength Tylenol Meltaways * juniper natural remedy ; K + 10 * K-Dur 10 * K-Dur 20 * K-Lor * K-Lyte * K-Lyte Cl * K-Norm * K-Pek II K-Tab * Kabikinase Kadian * Kaletra Capsules Kaletra Oral Solution kanamycin, injection Kantrex Injection Kao-Paverin Kaochlor 10% * Kaochlor S-F * Kaon * Kaon-Cl * Kaon-Cl-10 * Kaopectate Kaopectate Extra Strength Kariva * kava natural remedy ; Kay Ciel * Kaybovite-1000 Kayexalate Kayexalate Rectal Keep Alert Keflex * Kelnor * kelp natural remedy ; Kemadrin * Kemstro * Kenalog Topical * Kepivance Keppra Keralyt * Kerlone * Ketek ketoconazole, oral * ketoconazole, topical * Ketoprofen ER * ketoprofen, oral * ketorolac tromethamine, ophthalmic * ketorolac, injection ketorolac, oral ketotifen fumarate, ophthalmic * Kid Kare Children's Cough Cold * Kineret Kinesed Kionex Klaron Lotion * Klonopin and plavix and Order innopran online.
Table 2. Drug Therapy for Treatment of EGUS.
Continuing Medical Education, University of Minnesota, Box 293, 420 Delaware Street S.E., Minneapolis, MN 55455 612 ; 373-8012 and plendil.
Particularly among younger injectors. The proportion of new study recruits reporting heroin as their primary injection drug increased from 61 percent in 1994 to 86 percent in 1999. Among injectors younger than 20, the proportion reporting heroin increased from 78 to 100 percent in 1998. Among Chicago infants tested for controlled substances, opioid toxicity remained stable between 1997 and 1998 9 percent positive.
Drug Req. Drug Name Tier Limits WYTENSIN 3 YOHIMAR 3 QL AGENTS FOR PHEOCHROMOCYTOMA Brands DEMSER 3 DIBENZYLINE 3 PHENTOLAMINE MESYLATE 3 ANGIOTENSIN II RECEPTOR BLOCKERS Brands BENICAR 2 BENICAR HCT 2 COZAAR 2 HYZAAR 2 ATACAND 3 ATACAND HCT 3 AVALIDE 3 AVAPRO 3 DIOVAN 3 DIOVAN HCT 3 MICARDIS 3 MICARDIS HCT 3 TEVETEN 3 TEVETEN HCT 3 BETA BLOCKERS Generics acebutolol HCl 1 atenolol 1 betaxolol HCl 1 bisoprolol fumarate 1 labetalol HCl 1 metoprolol tartrate 1 nadolol 1 naldol 1 pindolol 1 propranolol HCl 1 timolol maleate 1 Brands COREG 2 TOPROL XL 2 BLOCADREN 3 CORGARD 3 INDERAL 3 INDERAL LA 3 INNOPRAN XL 3 KERLONE 3 LEVATOL 3.
DISCLOSURE: J.I. Peters, None. BURDEN OF ASTHMA IN THE ELDERLY Archana Mishra, MD, MS * ; Joshua Novak, MD; Patricia Nowak, RN; Alan T. Aquilina, MD; Brydon J. Grant, MD. Erie County Medical Center, Buffalo, NY PURPOSE: Rapid increases in the numbers and proportions of elderly in the U.S. have lead to concerns about the impact of these changes on use of health services and the burden of chronic disease. To determine the health care utilization patterns among elderly asthmatics in the Upstate New York area. METHODS: Outpatient health care utilization patterns were determined using Medicare claims data in 45 counties in upstate New York from 9 1 using the International Classification of Diseases code of 493 for asthma. Medicare is the major health insurance provider for this age group so the prevalence of asthma based on outpatient claims was calculated for the different counties using the population census data. RESULTS: There were 67, 000 claims that met this criteria. Using this set of claims the corresponding beneficiary and patient ID numbers were identified. There were 27, 669 unique identifiers in this set. From the table of patient information, the zip code for each patient was extracted and it was used to identify which county the patient lived in, and this allowed the data to be summarized by county prevalence. The gender distribution among asthmatics showed a preponderance of female gender, 67% versus 33% male. Only 9, 884 36% ; had spirometry performed. 3, 462 out of the 27, 669 with asthma also had claims for heart failure showing the increased prevalence of co-morbidities in this population. CONCLUSIONS: Spirometry claims suggest under use of objective testing in a cohort that needs it the most, given the comorbidities that make diagnosis and management of asthma a challenge in the elderly.
A. ACTIVITIES OF DEPARTMENT OF DRUG ADMINISTRATION Department of Drug Administration DDA ; has been implementing the Drug Act 1978 and its regulations. The various administrative and regulatory activities carried out by DDA and its branch offices at Biratnagar, Nepalgunj and Birganj during fiscal year 2062 063 July 2005 to June 2006 ; are given as follows: 1. Number of registered Pharmacy Outlets upto Ashad 2063.
Workers in some specific occupations seem to have a higher risk of developing arthritis than other jobs. These are primarily high demand jobs such as assembly line workers and heavy construction and buy atacand.
We thank Patrice Courvalin for supplying us with the probes used in this study. We also thank Thora Capper for assistance with MICs. This work was supported by the Medical Research Council and the South African Institute for Medical Research.
Dr K. Lewis Bell Director, Family Health Services, Ministry of Health Ms P. Davies First Secretary, Permanent Mission, Geneva Ms S. Betton First Secretary, Permanent Mission, Geneva Mrs F. Bell Southern Regional Health Authority, Ministry of Health.
Plain Language The court's first and foremost argument was based on the plain language of Section 340.6 and Evidence Code Section 500. The court pointed out that Section 340.6 establishes an affirmative defense of the statute of limitations. Id. at 7. Under Evidence Code Section 500, the defendant normally bears the burden of proof on an affirmative defense: "Except as otherwise provided by law, a party has the burden of proof as to each fact the existence or nonexistence of which is essential to the claim for relief or defense that he is asserting." Here, the court construed the one-year limitations defense of Section 340.6 to require proof of the time of discovery of the facts constituting malpractice. "In plain language, section 340.6 a ; makes essential to that defense the fact that any attorney malpractice action against which it is invoked was not `commenced within one year after the plaintiff discovers, or through the use of reasonable diligence should have discovered, the facts constituting the wrongful act or omission ." Id. The court thus concluded that the attorney-defendant bears the burden of proving the time of discovery, because Section 340.6 must be construed "in accordance with its plain language . and the normal allocation of the burden of proof established by the Legislature ." Id. at 7-8. Common Law Discovery Rule In Laird v. Blacker, 2 Cal. 4th 606, 611, P.2d 691, 7 Cal. Rptr. 2d 550 1992 ; , the court commented that "when the Legislature adopted section 340.6 in 1977, it implicitly . codified the discovery rule of Neel ." Relying on that remark, the defendant in Samuels v. Mix contended that "in enacting section 340.6, the Legislature intended that burdens of proof thereunder be allocated just as they have been allocated under the common law discovery rule ." 22 Cal. 4th at 9. The defendant thus maintained that the plaintiff bears the burden of proving the time of discovery under Section 340.6, because "in applying the common law discovery rule, California courts generally have burdened plaintiffs with justifying any undue delay in filing their complaints." Id. at 10; see, e.g., April Enterprises, Inc. v. KTTV, 147 Cal. App. 3d 805, 832-33, Cal. Rptr. 421 1983 ; . The Supreme Court disagreed. It rejected "the sweeping notion that all common law appendages to the discovery rule are automatically pertinent under section 340.6." Samuels v. Mix, 22 Cal. 4th at 12. Rather, "the Legislature clearly intended more than merely to codify the common law discovery rule, because section 340.6 a ; , even absent discovery, absolutely cuts off actions after a 6.
CONTENT DESCRIPTION Infection prevention is an essential strategy to improve patient safety, especially in the critical care patient population. Critically ill patients are at higher risk for ventilator associated pneumonia, and infections in the bloodstream, urinary tract, and surgical site. The incidence of Infection with drug-resistant organisms is also rising. Chlorhexidine Gluconate CHG ; is being increasingly studied and used in successful infection prevention programs. This session reviews the evidence related to use of CHG to prevent these common infections. LEARNING OUTCOMES At the end of the session the participant will be able to: 1. Discuss the etiology of common infections in the critically ill patient, including the role of biofilms. 2. Describe the research related to the effectiveness of CHG in infection prevention. 3. Identify best practice strategies for preventing common infections. SUMMARY OF KEY POINTS I. Infection Prevention: Important for all II. Etiology of infections in critically ill patients A. Ventilator-associated pneumonia VAP ; B. Catheter-related bloodstream infections CR-BSI ; C. Surgical site infections SSI ; D. Urinary tract infections UTI ; III. Common organisms for each infection IV. Increasing development of infections with multidrug resistant organisms V. Role of biofilms in infection A. Thin, usually resistant layer of microorganisms that form and coat on various surfaces B. Devices surfaces implicated in wide variety of infections 1. Endotracheal tube 2. Teeth and gums 3. Central lines 4. Skin 5. Indwelling catheters VI. Is CHG the answer to preventing infection? A. How CHG works B. Role in common infections C. Effectiveness on biofilms D. Effectiveness on mutidrug resistant organisms E. Summary of latest evidence related to CHG in infection prevention.
Elidel pimecrolimus ; protopic tacrolimus ; beta blockers betapace sotalol ; betaxolol bisoprolol blocadren timolol ; cartrol carteolol ; corgard nadolol ; innopran xl propranolol ; kerlone betaxolol ; levatol penbutolol ; lopressor metoprolol ; sectral acebutolol ; tenormin atenolol ; zebeta bisoprolol ; beta- and alpha- blockers normodyne labetalol ; trandate labetalol ; if one of the exceptions on the pa form is present or if the physician feels that the patient cannot be stabilized with any of the preferred agents, one of the non-preferred agents will be approved.
Strategy for docetaxel this search retrieved 212 references.
Decision to treat CHF vs: COPD is based on the weight of evidence considering the following: -1-Has One of these been predominant in the past? -2-Meds-You must be capable of identifying meds. -3-Presence of orthopnea - increased difficulty in breathing when in the supine position. -4-BS-Rales-Fine expiratory sounds. -5-Wheezes- Prolonged expiration. -6-Rhonchi- Harsh inspiratory that can be "tracked" to upper airways. -7-Stridor-Inspiratory - upper airway harsh sounds.
BETA-ADRENERGIC BLOCKING AGENTS BETA-ADRENERGIC BLOCKING AGENTS TIER NOTES BRAND COREG CR 2 TENORMIN I.V. 2 BETAPACE 3 BETAPACE AF 3 BYSTOLIC 3 CARTROL 3 COREG 3 CORGARD 3 CORZIDE 3 INDERAL 3 INDERAL LA 3 INDERIDE-40 25 3 INNOPRAN XL 3 KERLONE 3 LEVATOL 3 LOPRESSOR 3 LOPRESSOR HCT 3 PROPRANOLOL HCL 120mg 3 cap.sa PROPRANOLOL HCL solution 3 PROPRANOLOL HCL vial 3 SECTRAL 3 TENORETIC 100 3 TENORETIC 50 3 TENORMIN 3 TIMOLIDE 3 TRANDATE 3 ZEBETA 3 ZIAC 3 CALCIUM-CHANNEL BLOCKING AGENTS CALCIUM-CHANNEL BLOCKING AGENTS, MISC. cartia xt 1 dilt-cd 1 diltia xt 1.
Patients will receive intravenous study treatment zoledronic acid ; for a total duration of 48 months or no treatment control group ; . After the development of bone metastases in the control group, it is recommended to treat all patients with 4 mg zoledronic acid.
The immune response to the opportunistic pulmonary pathogen Pneumocystis can have beneficial and harmful effects on the host despite the presence of corticosteroids. We hypothesized that this deleterious hyperinflammatory response is associated with exaggerated cytokine production. The adoptive transfer of at least 107 immune splenocytes reduced the cyst count in rats with corticosteroid-induced pneumocystosis. About 18% of these rats developed clinical illness, an increased lung weight body weight LW BW ; ratio, and elevated levels of interleukin 1 IL-1 ; , IL-1 , IL-6, tumor necrosis factor alpha, IL-5, IL-10, and gamma interferon in the lungs. This hyperinflammatory reaction was not observed in rats that remained clinically well or in control rats. Thus, in this model, corticosteroids have little effect on the cytokine cascade or other adverse effects of the host immune response to Pneumocystis. Human immunodeficiency virus HIV ; -infected persons with low CD4 -cell counts and patients who receive corticosteroids CS ; for the treatment of diseases such as cancer and organ transplantation are susceptible to pneumonia caused by the extracellular fungal pathogen Pneumocystis. Yet there is increasing recognition that the host's immune responses to Pneumocystis can have harmful, as well as helpful, effects on the lung. Symptoms of Pneumocystis pneumonia in non-HIV patients often do not begin until after CS have been tapered off 36 ; . Increased levels of neutrophils and IL-8, a potent chemoattractant, in the bronchoalveolar lavage fluid BALF ; of HIV patients with Pneumocystis pneumonia are associated with a worse prognosis 6 ; . HIV patients with Pneumocystis pneumonia experience worsening of respiratory function soon after receiving anti-Pneumocystis drugs, and this can be prevented by CS 1 ; HIV patients who have recovered from Pneumocystis pneumonia and are started on highly active antiretroviral therapy may develop the "immune reconstitution syndrome, " which is characterized by pulmonary infiltrates leading to respiratory impairment 38 ; . Rodent models have proven to be useful in studying the dual effects of the host immune response to Pneumocystis and the role of CD4 and other cells in this response 2, 11, 13, ; . One experimental approach has involved the adoptive transfer of immune splenocytes or purified T-cell populations into athymic nude ; or severe-combined-immunodeficiency SCID ; mice with Pneumocystis pneumonia. The first study to demonstrate this was that of Furuta et al. 9 ; , in which splenocyte transfer to nude Pneumocystis pneumonia mice reduced the Pneumocystis cyst burden but caused intense cellular reactions. Transfer of splenocytes in SCID Pneumocystis pneumonia mouse models also successfully lowered the organism burden with potentially damaging cellular infiltration of the lungs 23, 40, 41 ; . When purified CD4 T cells were utilized as donor cells to recipient SCID mice, a greater reduction of organism burden occurred, but it was accompanied by a hyperinflammatory reaction HIR ; , evidenced by increased lung weight body weight LW BW ; ratios that led to premature death 23 ; . CD8 -T-cell adoptive transfer in the SCID mouse Pneumocystis pneumonia model, on the other hand, had no effect on either the Pneumocystis burden or the host lung 23 ; . A second approach has involved depletion of CD4 and or CD8 cells to induce Pneumocystis pneumonia in normal mice. Anti-CD4 -T-cell antibody Ab ; treatment with GK1.5 rendered mice susceptible to Pneumocystis 27 ; , with an intense inflammatory response that involved CD8 cells and gamma interferon IFN- ; 2 ; , while anti-CD8 -T-cell Ab treatment with YTS169.4 alone had no effect 3, 39 ; . Mice depleted of both CD4 and CD8 T cells developed more severe Pneumocystis pneumonia, but inflammatory responses were varied depending on the mouse strain, suggesting that CD8 cells played an interactive role with CD4 cells in controlling Pneumocystis infection and lung inflammation 3, 39, 42 ; . Our laboratory has used a different experimental approach that involves the administration of CS to induce Pneumocystis pneumonia in normal rats. In some respects, this model better mimics HIV than the mouse models described above. CS have broad immunosuppressive effects, but some degree of host immune function is preserved. These agents also have complex enhancing or suppressing ; effects on cytokine function, depending on the conditions of the experiment 7 ; . CS are given throughout an experiment and will have an effect on any immunologic manipulation of the host. Rather than being administered as freshly obtained cells, immune splenocytes are first sensitized to a specific Pneumocystis antigen, the major surface.
Speed manual gearbox and two-speed transfer box. New Zealand: In June 2005 the Special Air Service deployed its newly delivered Pinzgauer 6 special operations vehicles for the first time to conduct longrange reconnaissance and direct action missions in Afghanistan. The British company bought in April 2005 by Stewart.
Aktiengesellschaft, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration. In a letter dated May 17, 1999, FDA advised the Patent and Trademark Office that this human drug product had undergone a regulatory review period and that the approval of Arava represented the first permitted commercial marketing or use of the product. Shortly thereafter, the Patent and Trademark Office requested that FDA determine the product's regulatory review period. FDA has determined that the applicable regulatory review period for Arava is 2, 032 days. Of this time, 1, 908 days occurred during the testing phase of the regulatory review period, while 124 days occurred during the approval phase. These periods of time were derived from the following dates: 1. The date an exemption under section 505 of the Federal Food, Drug, and Cosmetic Act the act ; 21 U.S.C. 355 ; became effective: February 18, 1993. The applicant claims February 14, 1993, as the date the investigational new drug application IND ; became effective. However, FDA records indicate that the IND effective date was February 18, 1993, which was 30 days after FDA receipt of the IND. 2. The date the application was initially submitted with respect to the human drug product under section 505 of the act: May 10, 1998. FDA has verified the applicant's claim that the new drug application NDA ; for Arava NDA 20905 ; was initially submitted on May 10, 1998. 3. The date the application was approved: September 10, 1998. FDA has verified the applicant's claim that NDA 20905 was approved on September 10, 1998. This determination of the regulatory review period establishes the maximum potential length of a patent extension. However, the U.S. Patent and Trademark Office applies several statutory limitations in its calculations of the actual period for patent extension. In its application for patent extension, this applicant seeks 1, 110 days of patent term extension. Anyone with knowledge that any of the dates as published is incorrect may, on or before March 27, 2000, submit to the Dockets Management Branch address above ; written comments and ask for a redetermination. Furthermore, any interested person may petition FDA, on or before July 25, 2000, for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period. To meet its burden, the petition.
Attempt is inherent in depression and may persist until significant remission occurs. This risk must be.
Innopran therapy
Lnnopran, innoprab, innpran, 9nnopran, innlpran, innopdan, innoprn, ijnopran, innopram, innopfan, iinnopran, inn0pran, innop5an, innoprran, innipran, innoprqn, injopran, innnopran, innopra, onnopran, innorpan, knnopran, innoprah, innoprxn, innnopran, innkpran, innoran, jnnopran, inopran, imnopran, unnopran.
|
|
